Figure 6
Adoptive transfer of γ9δ2 T cells in combination with CD19BiTE attenuates extramedullary disease. (a) Schematic representation of the experimental schedule. Adult NOG mice (40 weeks old, male) were injected with Raji/eGFP-fLuc tumor cells (2.5 × 105 cells/mouse) through the lateral tail vein (i.v.). On day eight post tumor injection, mice received daily treatment of two i.v. doses of CD19BiTE (250 ng/dose/mouse) and an i.v. dose of γ9δ2 T cells (2.5 × 106 cells/mouse) for six consecutive days (n = 3), or left untreated as controls (n = 2). γ9δ2 T cells were expanded from two donors’ peripheral blood mononuclear cells. A single mouse was treated with the γ9δ2 T cells derived from the same donor at different time points. (b) Bioluminescence images (BLI) were taken for each mouse on days 7 and 14 after tumor injection. The total flux (photons/sec) of tumor cells in the whole body (c) or the area outside the bone marrow (d) was calculated as the sum of bioluminescence signal intensity. Data were plotted as mean ± s.d., and the statistical analysis was performed by two-way analysis of variance (ANOVA) followed by Sidak’s multiple comparison tests (**: p = 0.0011; ***: p = 0.0008; n.s.: not significant).
